The OHSU Knight Cancer Institute is on the leading edge of discovering new ways to prevent, detect and treat cancer. With over 400 clinical trials in progress, we are searching for new cures, standards of care, treatments and therapies for cancer.
Our mission statement
At the OHSU Knight Cancer Institute, our mission is to end cancer as we know it. As pioneers in personalized cancer medicine, we continue to change the way the world understands and fights this disease. We will:
- Provide individually-tailored, compassionate care for every patient, from diagnosis through survivorship.
- Discover new ways to prevent cancer.
- Develop new personalized cancer therapies.
Knight Cancer history
The OHSU Knight Cancer Institute became Oregon’s only NCI-designated cancer center in 1997. The institute is known internationally for its leadership in fighting cancer at the molecular level. The most celebrated cancer discovery in a generation—the targeted drug Gleevec—was developed at OHSU by Brian J. Druker, M.D., the director of the OHSU Knight Cancer Institute and JELD-WEN Chair of Leukemia Research. Druker also is a member of the National Academy of Sciences and a Howard Hughes Medical Investigator.